Abstract
Background:
Fibroblast growth factor (FGF) 21 is an endocrine factor with an emerging role as a metabolic regulator. We previously reported the presence of a significant day/night variation of FGF-21 in energy-replete, healthy female subjects. However the day/night patterns of secretion in male subjects remain to be fully elucidated. To elucidate day/night pattern of FGF-21 levels in male subjects in the energy-replete state, its relationship to FFA and to investigate whether a sexual dimorphism exists in FGF-21 physiology.
Methods:
Eight healthy lean male subjects were studied for up to 5 days while on an isocaloric diet. Blood samples were obtained for measurement of FGF-21 and free fatty acids (FFA) hourly from 0800 AM on day 4 till 0800AM on day 5.
Results:
FGF-21 did not exhibit any statistically significant day/night variation pattern of circulating FGF-21 levels during the isocaloric fed state in male subjects. FGF-21 levels in male subjects are closely cross-correlated with FFA levels, similar to female subjects.
Conclusions:
A sexual dimorphism exists in FGF-21 physiology; that as opposed to female subjects, no significant day/night variation exists in FGF-21 rhythm in male subjects in the energy-replete state. Circulating pattern of FGF-21, similar to the female subjects, was highly cross-correlated to the FFA levels in the male subjects, signifying that the sexual dimorphism in FGF-21 physiology may be related to the differing lipid metabolism in both the genders.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Kharitonenkov A, Shiyanova TL, Koester A, Ford AM, Micanovic R, Galbreath EJ et al. FGF-21 as a novel metabolic regulator. J Clin Invest 2005; 115: 1627–1635.
Kim KH, Kim SH, Min YK, Yang HM, Lee JB, Lee MS . Acute exercise induces FGF21 expression in mice and in healthy humans. PloS One 2013; 8: e63517.
Potthoff MJ, Inagaki T, Satapati S, Ding X, He T, Goetz R et al. FGF21 induces PGC-1alpha and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. Proc Natl Acad Sci USA 2009; 106: 10853–10858.
Xu J, Lloyd DJ, Hale C, Stanislaus S, Chen M, Sivits G et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 2009; 58: 250–259.
Zhang X, Yeung DC, Karpisek M, Stejskal D, Zhou ZG, Liu F et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 2008; 57: 1246–1253.
Fisher FM, Chui PC, Antonellis PJ, Bina HA, Kharitonenkov A, Flier JS et al. Obesity is a fibroblast growth factor 21 (FGF21)-resistant state. Diabetes 2010; 59: 2781–2789.
Galman C, Lundasen T, Kharitonenkov A, Bina HA, Eriksson M, Hafstrom I et al. The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man. Cell Metab 2008; 8: 169–174.
Mai K, Andres J, Biedasek K, Weicht J, Bobbert T, Sabath M et al. Free fatty acids link metabolism and regulation of the insulin-sensitizing fibroblast growth factor-21. Diabetes 2009; 58: 1532–1538.
Yu H, Xia F, Lam KS, Wang Y, Bao Y, Zhang J et al. Circadian rhythm of circulating fibroblast growth factor 21 is related to diurnal changes in fatty acids in humans. Clin Chem 57: 691–700.
Foo JP, Aronis KN, Chamberland JP, Paruthi J, Moon HS, Mantzoros CS . Fibroblast growth factor 21 levels in young healthy females display day and night variations and are increased in response to short-term energy deprivation through a leptin-independent pathway. Diabetes Care 2013; 36: 935–942.
Wang X, Magkos F, Mittendorfer B . Sex differences in lipid and lipoprotein metabolism: it's not just about sex hormones. J Clin Endocrinol Metab 2011; 96: 885–893.
Jensen MD, Johnson CM . Contribution of leg and splanchnic free fatty acid (FFA) kinetics to postabsorptive FFA flux in men and women. Metab Clin Exp 1996; 45: 662–666.
Jensen MD, Cryer PE, Johnson CM, Murray MJ . Effects of epinephrine on regional free fatty acid and energy metabolism in men and women. Am J Physiol 1996; 270: E259–E264.
Mittendorfer B, Horowitz JF, Klein S . Gender differences in lipid and glucose kinetics during short-term fasting. Am J Physiol Endocrinol Metab 2001; 281: E1333–E1339.
Horton TJ, Dow S, Armstrong M, Donahoo WT . Greater systemic lipolysis in women compared with men during moderate-dose infusion of epinephrine and/or norepinephrine. J Appl Physiol 2009; 107: 200–210.
Zauner C, Schneeweiss B, Kranz A, Madl C, Ratheiser K, Kramer L et al. Resting energy expenditure in short-term starvation is increased as a result of an increase in serum norepinephrine. Am J Clin Nutr 2000; 71: 1511–1515.
Chan JL, Mietus JE, Raciti PM, Goldberger AL, Mantzoros CS . Short-term fasting-induced autonomic activation and changes in catecholamine levels are not mediated by changes in leptin levels in healthy humans. Clin Endocrinol (Oxf) 2007; 66: 49–57.
Schlierf G, Dorow E . Diurnal patterns of triglycerides, free fatty acids, blood sugar, and insulin during carbohydrate-induction in man and their modification by nocturnal suppression of lipolysis. J Clin Invest 1973; 52: 732–740.
Boyle PJ, Avogaro A, Smith L, Bier DM, Pappu AS, Illingworth DR et al. Role of GH in regulating nocturnal rates of lipolysis and plasma mevalonate levels in normal and diabetic humans. Am J Physiol 1992; 263: E168–E172.
Hagstrom-Toft E, Bolinder J, Ungerstedt U, Arner P . A circadian rhythm in lipid mobilization which is altered in IDDM. Diabetologia 1997; 40: 1070–1078.
Koutsari C, Basu R, Rizza RA, Nair KS, Khosla S, Jensen MD . Nonoxidative free fatty acid disposal is greater in young women than men. J Clin Endocrinol Metab 2011; 96: 541–547.
Andersen B, Beck-Nielsen H, Hojlund K . Plasma FGF21 displays a circadian rhythm during a 72-h fast in healthy female volunteers. Clin Endocrinol (Oxf) 2011; 75: 514–519.
Huang J, Ishino T, Chen G, Rolzin P, Osothprarop TF, Retting K et al. Development of a novel long-acting antidiabetic FGF21 mimetic by targeted conjugation to a scaffold antibody. J Pharmacol Exp Therapeut 2013; 346: 270–280.
Smith R, Duguay A, Weiszmann J, Stanislaus S, Belouski E, Cai L et al. A novel approach to improve the function of FGF21. BioDrugs 2013; 27: 159–166.
Hecht R, Li YS, Sun J, Belouski E, Hall M, Hager T et al. Rationale-based engineering of a potent long-acting FGF21 analog for the treatment of Type 2 diabetes. PloS One 2012; 7: e49345.
Korkmaz A, Topal T, Tan DX, Reiter RJ . Role of melatonin in metabolic regulation. Rev Endocr Metab Disord 2009; 10: 261–270.
Gangwisch JE, Feskanich D, Malaspina D, Shen S, Forman JP . Sleep duration and risk for hypertension in women: results from the nurses' health study. Am J Hypertens 2013; 26: 903–911.
Scheer FA, Hilton MF, Mantzoros CS, Shea SA . Adverse metabolic and cardiovascular consequences of circadian misalignment. Proc Natl Acad Sci USA 2009; 106: 4453–4458.
Acknowledgements
This study was supported by the National Institutes of Health National Center for Research Resources grant M01-RR-01032 (Harvard Clinical and Translational Science Center). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Research Resources or the National Institutes of Health. Clinical trial registration: NCT00140231.
Author Contributions
JPF wrote manuscript, researched data, performed lab work; KNA analyzed the data, wrote manuscript; JPC peformed lab work; CSM is the principal investigator, designed and supervised the study and reviewed and edited the manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of intrest.
Rights and permissions
About this article
Cite this article
Foo, JP., Aronis, K., Chamberland, J. et al. Lack of Day/Night variation in fibroblast growth factor 21 levels in young healthy men. Int J Obes 39, 945–948 (2015). https://doi.org/10.1038/ijo.2014.215
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/ijo.2014.215